NCT00001019View on ClinicalTrials.gov

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
BIOLOGICAL

rgp120/HIV-1 SF-2

BIOLOGICAL

MTP-PE/MF59

Trial Locations (4)

19104

Univ of Pennsylvania at Philadelphia, Philadelphia

37232

Vanderbilt Univ Hosp, Nashville

63104

St Louis Univ School of Medicine, St Louis

981050371

Children's Hospital & Medical Center / Seattle ACTU, Seattle

Sponsors

Collaborators (1)

Biocine
All Listed Sponsors
collaborator

Biocine

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001019 - Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant | Biotech Hunter | Biotech Hunter